1 / 10

Stock

Stock. CBS, ASIA, DNDN Jasmine Kaohelaulii. ASIA.

oriana
Download Presentation

Stock

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stock CBS, ASIA, DNDN Jasmine Kaohelaulii

  2. ASIA • Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to improve cancer treatment options for patients. The company’s product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates include Provenge, an active cellular immunotherapy that has completed two phase 3 trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), an investigational active immunotherapy for the treatment of patients with breast, ovarian, and other solid tumors expressing HER2/neu. The company also has a range of products in preclinical studies, which include CEA for the treatment of breast, lung, and colon cancer; CA-9 (MN) for the treatment of kidney, colon, and cervical cancer; Anti-Serine Protease for the treatment of multiple cancers; and Anti-HLA-DR for the treatment of hematologic malignancies, as well as TRPM8 for the treatment of lung, breast, prostate, and colon cancer. Dendreon Corporation was formerly known as Activated Cell Therapy, Inc. The company was founded in 1992 and is headquartered in Seattle, Washington.

  3. ASIA • Name of the stock- Asiainfo holdings Inc. • Current Price of the Stock-$16.50 • EPS-0.40 • Beta- 0.98 • PE-40.94

  4. CBS • CBS Corporation operates as a mass media company in the United States and internationally. The company operates in five segments: Television, Radio, Outdoor, Interactive, and Publishing. The Television segment operates through CBS Television comprising CBS Television Networks, the 30 owned broadcast television stations; CBS Paramount Network Television and CBS Television Distribution, the television production and syndication operations; Showtime Network, a premium subscription television program service; and CBS College Sports Network, the cable network and online digital media business to college athletics. The Radio segment operates through CBS radio, which owns and operates 137 radio stations in the United States. Its programs include rock, oldies, all-news, talk, adult contemporary, urban, and sports and country. The Outdoor segment displays advertising on media, including billboards, transit shelters, buses, rail systems, mall kiosks, stadium signage, and in retail stores. It provides its services to entertainment, media, automotive, beverage, financial, real estate, retail, healthcare, telecommunications, restaurants, health and beauty aids, hotels, and professional services. The Interactive segment operates an online content network for information and entertainment with a portfolio of brands, including CNET, CBS.com, CBSSports.com, GameSpot, TV.com, Last.fm, and BNET. The Publishing segment publishes and distributes adult and children's consumer books in printed, audio, and digital formats under the Simon & Schuster, Pocket Books, Scribner, Atria Books, Simon Spotlight Entertainment, Free Press, Simon Spotlight, Aladdin Paperbacks, and Books for Young Readers imprints. The company was founded in 1986 and is headquartered in New York, New York.

  5. CBS • CBS Corporation • Current Price of the Stock- $4.85 • EPS- -17.43 • Beta-1.59 • PE-N/A

  6. DNDN • Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to improve cancer treatment options for patients. The company’s product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates include Provenge, an active cellular immunotherapy that has completed two phase 3 trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), an investigational active immunotherapy for the treatment of patients with breast, ovarian, and other solid tumors expressing HER2/neu. The company also has a range of products in preclinical studies, which include CEA for the treatment of breast, lung, and colon cancer; CA-9 (MN) for the treatment of kidney, colon, and cervical cancer; Anti-Serine Protease for the treatment of multiple cancers; and Anti-HLA-DR for the treatment of hematologic malignancies, as well as TRPM8 for the treatment of lung, breast, prostate, and colon cancer. Dendreon Corporation was formerly known as Activated Cell Therapy, Inc. The company was founded in 1992 and is headquartered in Seattle,Washington.

  7. DNDN • Dendreon Corporation • Current price of Stock-$6.58 • EPS- -0.79 • PE- N/A • Beta- 1.55

More Related